Get the Stockscreener App
2.69
2.18%
-0.06
Pre-market:
2.80
0.11
+4.09%
Acelyrin Inc stock is traded at $2.69, with a volume of 970.81K.
It is down -2.18% in the last 24 hours and up +30.58% over the past month.
Acelyrin Inc is a late-stage clinical biopharmaceutical company. It is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of of transformative medicines.
See More
Previous Close:
$2.75
Open:
$2.77
24h Volume:
970.81K
Relative Volume:
0.48
Market Cap:
$269.88M
Revenue:
-
Net Income/Loss:
$-299.80M
P/E Ratio:
-0.9472
EPS:
-2.84
Net Cash Flow:
$-217.49M
1W Performance:
+1.13%
1M Performance:
+30.58%
6M Performance:
-42.77%
1Y Performance:
-67.35%
1-Day Range:
$2.67
$2.795
1-Week Range:
$2.54
$2.7999
52-Week Range:
$1.845
$8.59
Acelyrin Inc Stock (SLRN) Company Profile
Name
Acelyrin Inc
Sector
Industry
Phone
805-871-4300
Address
4149 LIBERTY CANYON RD., AGOURA HILLS
Compare SLRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLRN
Acelyrin Inc
|
2.69 | 269.88M | 0 | -299.80M | -217.49M | -2.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Acelyrin Inc Stock (SLRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-08-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-08-23 | Initiated | Citigroup | Neutral |
| Sep-13-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-05-23 | Initiated | H.C. Wainwright | Buy |
| May-30-23 | Initiated | Jefferies | Buy |
| May-30-23 | Initiated | Morgan Stanley | Overweight |
| May-30-23 | Initiated | Piper Sandler | Overweight |
| May-30-23 | Initiated | TD Cowen | Outperform |
View All
Acelyrin Inc Stock (SLRN) Latest News
Drug developers Pliant and Acelyrin adopt poison pill provisions to fend off activist investor - San Francisco Business Times
Acelyrin Adopts Poison Pill to Ward Off Tang Capital Buy - BioSpace
Acelyrin stock in focus after poison pill (SLRN:NASDAQ) - Seeking Alpha
Acelyrin Adopts Stockholder Rights Plan; Shares Up Pre-Bell -March 13, 2025 at 08:09 am EDT - Marketscreener.com
Acelyrin adopts rights plan in response to Tang Capital stake - Investing.com India
Acelyrin adopts rights plan in response to Tang Capital stake By Investing.com - Investing.com South Africa
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan - The Manila Times
Acelyrin: Potential Buyout Led By Concentra Biosciences (NASDAQ:SLRN) - Seeking Alpha
How a skin drug trial could help Peninsula biotech pull off key merger - The Business Journals
Is Acelyrin, Inc. (SLRN) the Best Micro Cap Stock to Buy Now? - Insider Monkey
Acelyrin, Alumis reaffirm strategic, financial rationale of proposed merger - TipRanks
New York State Common Retirement Fund Lowers Position in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
10 Best Micro Cap Stocks to Buy Now - Insider Monkey
Acelyrin falls as Acelyrin reaffirms deal commitment - MSN
Acelyrin rebuffs Concentra bid, believing Alumis option better - The Pharma Letter
Acelyrin Rejects Concentra’s Buyout Offer in Favor of Alumis Merger - BioSpace
Acelyrin To Proceed With Alumis Merger, Spurn Concentra Bid - Citeline News & Insights
Sector Update: Health Care Stocks Lower Tuesday Afternoon -March 04, 2025 at 02:01 pm EST - Marketscreener.com
Acelyrin Reaffirms Merger Deal With Alumis -March 04, 2025 at 10:13 am EST - Marketscreener.com
Acelyrin stock falls on Acelyrin deal commitment (SLRN:NASDAQ) - Seeking Alpha
Alumis Inc. Announces Merger with ACELYRIN, Inc. - TipRanks
Acelyrin says Concentra indication not expected to result in superior proposal - TipRanks
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger - The Manila Times
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger - The Manila Times
Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger - The Manila Times
Alumis Inc. and ACELYRIN, Inc. Confirm Commitment to All-Stock Merger to Create Leading Biopharma Company in Immune-Mediated Diseases - Nasdaq
Alumis And Acelyrin Reaffirm Strategic And Financial Rationale Of Proposed Merger -March 04, 2025 at 09:06 am EST - Marketscreener.com
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not ... - Eagle-Tribune
Can This Biopharma Merger's $737M War Chest Transform Immune Disease Treatment? - StockTitan
Acelyrin stock down after reaffirming Alumis deal (SLRN:NASDAQ) - Seeking Alpha
SHAREHOLDER ALERT: Potential Recovery for Acelyrin, Inc. (SLRN) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
INVESTOR ALERT: Levi & Korsinsky Notifies Acelyrin, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineSLRN - ACCESS Newswire
INVESTOR ALERT: Levi & Korsinsky Reminds Acelyrin, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 16, 2024SLRN - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 16, 2024 in Acelyrin LawsuitSLRN - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Acelyrin, Inc. (SLRN) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Reminds Acelyrin, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 16, 2024SLRN - ACCESS Newswire
SHAREHOLDER ALERT: Potential Recovery for Acelyrin, Inc. (SLRN) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
INVESTOR ALERT: Potential Recovery for Acelyrin, Inc. (SLRN) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Counteroffer from Tang-backed Concentra could scuttle Acelyrin-Alumis: Deals Report - BioCentury
Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week - NewsBreak
Activist investor threatens drug maker's merger plans with L.A. biotech - L.A. Business First
Activist investor threatens Peninsula drug maker's merger plansSan Francisco Business Times - The Business Journals
Concentra Biosciences, LLC made an Unsolicited Indication of Interest to acquire Acelyrin, Inc. from a group of shareholders for approximately $310 million. - Marketscreener.com
ACELYRIN shares surge on buyout interest By Investing.com - Investing.com Nigeria
ACELYRIN shares surge on buyout interest - Investing.com
Acelyrin Receives Unsolicited Buyout Offer From Concentra Biosciences -February 21, 2025 at 04:38 am EST - Marketscreener.com
Acelyrin confirms unsolicited indication of interest from Concentra Biosciences - TipRanks
Acelyrin Inc Stock (SLRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Acelyrin Inc Stock (SLRN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lin Shao-Lee | Chief Executive Officer |
Apr 01 '24 |
Sale |
6.63 |
9,961 |
66,024 |
1,577,374 |
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):